Authors of a review aimed to explore the clinical utility of deutetrabenazine in Huntington’s Disease (HD) and tardive dyskinesia (TD). Through summarizing clinical evidence, the authors walked through the efficacy in both disease types. Overall, the authors sited deutetrabenazine to be a safe and effective treatment for both TD and chorea in HD, with indirect comparisons showing relative superiority of deutetrabenazine over tetrabenazine for safety, though they do note that direct comparisons of efficacy and safety is needed between VMAT2 and dopamine blocking agents.

Reference: Frank S, Alakkas A. Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington’s Disease and Tardive Dyskinesia. Ther Clin Risk Manag. 2023;19:1019-1024. doi:10.2147/TCRM.S279332